Abstract
INTRODUCTION: The credibility of model-based economic evaluations of Alzheimer's disease (AD) interventions is central to appropriate decision-making in a policy context. We report on the International PharmacoEconomic Collaboration on Alzheimer's Disease (IPECAD) Modeling Workshop Challenge.
METHODS: Two common benchmark scenarios, for the hypothetical treatment of AD mild cognitive impairment (MCI) and mild dementia, were developed jointly by 29 participants. Model outcomes were summarized, and cross-comparisons were discussed during a structured workshop.
RESULTS: A broad concordance was established among participants. Mean 10-year restricted survival and time in MCI in the control group ranged across 10 MCI models from 6.7 to 9.5 years and 3.4 to 5.6 years, respectively; and across 4 mild dementia models from 5.4 to 7.9 years (survival) and 1.5 to 4.2 years (mild dementia).
DISCUSSION: The model comparison increased our understanding of methods, data used, and disease progression. We established a collaboration framework to assess cost-effectiveness outcomes, an important step toward transparent and credible AD models.
| Original language | English |
|---|---|
| Pages (from-to) | 1800-1820 |
| Number of pages | 21 |
| Journal | Alzheimer's & dementia : the journal of the Alzheimer's Association |
| Volume | 19 |
| Issue number | 5 |
| Early online date | 25 Oct 2022 |
| DOIs | |
| Publication status | Published - May 2023 |
Bibliographical note
Funding Information:IPECAD workshop 2 participants: name, short affiliation, country abbreviation (model acronym or not applicable (n/a)): Ali Tafazzoli, Evidera, UK and US (ADACE). Anders Gustavsson, QuantifyResearch and Karolinska Institutet, SE (IPECAD). Anders Sköldunger, Karolinska Institutet, SE (KP). Anders Wimo, Karolinska Institutet, SE (SVEDEM). Andreas Karlsson, Karolinska Institutet, SE (IPECAD). Bengt Winblad, Karolinska Institutet, SE (IPECAD). Bryan Tysinger, University of Southern California, US (FEM). Chiara Brück, Erasmus MC University Medical Center Rotterdam, NL (MISCAN). Colin Green, University of Exeter, UK (IPECAD). Eldon Spackman, University of Calgary, CA (n/a). Eric Jutkowitz, Brown, US (Jutkowitz et al.). Inge de Kok, Erasmus MC University Medical Center Rotterdam, NL (MISCAN). Jakub Hlávka, University of Southern California, US (FEM). Javier Mar, Basque Health Service, ES (BASQDEM). Jorgen Moller, Evidera, UK and US (ADACE). Linus Jönsson, Karolinska Institutet, SE (IPECAD). Mark Belger, Eli Lilly, UK (CEM). Matthew Davis, Medicus Economics, US (DAVIS et al.). Mauricio Lopez Mendez, Brown, US (JUTKOWITZ et al.). Michael Happich, Eli Lilly, DE (CEM). Myriam Soto-Gordoa, Mondragon Unibertsitatea, ES (BASQDEM). Pei-Jung Lin, Tufts Medical Center, US (n/a). Peter Shewmaker, Brown, US (Jutkowitz et al.). Raphael Wittenberg, London School of Economics, UK (CPEC). Robert Espinosa, Medicus Economics, US (DAVIS et al.). Robert Anderson, London School of Economics, UK (CPEC). Ron Handels, Maastricht University and Karolinska Institutet, NL and SE (IPECAD). Scott Johnson, Medicus Economics, US (DAVIS et al.). William L. Herring, RTI Health Solutions, US (HERRING et al.). We acknowledge all who contributed to the development of the models presented in this manuscript who were not part of the workshop. The authors are grateful to Michael Willis (The Swedish Institute for Health Economics, Sweden) for his special contribution to the first workshop for sharing his experience from the Mount Hood Diabetes Challenge Network.
Publisher Copyright:
© 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
